hDGAT2

Fig.1 Detection of DGAT2 expression in the liver and subcutaneous fat pad by RT-PCR. 

Wild type: only one band at 481 bp with primers F1/R1(mDgat2);

Heterozygous: one band at 481 bp with primers F1/R1(mDgat2) and one band at 388 bp with primers F2/R2(hDGAT2).

Abbr. M, DNA marker; HE, heterozygous; WT, wild type.

Fig.2 Detection of human DGAT2(A) and mouse Dgat2(B) mRNA expression in liver and WAT by qPCR. 

A：Relative expression was reported as the percentage to human DGAT2 mRNA levels in the liver of hDGAT2 knockin mice (n=2, male, 9-week-old). 

B：Relative expression was reported as the percentage to mouse Dgat2 mRNA levels in the liver of WT C57BL/6 mice (n=2, male, 9-week-old).

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig.3 Detection of human DGAT2 mRNA knockdown in liver and gWAT by qPCR. Female mice (8–9 weeks old) were assigned to three groups (n=2 per group). Homozygous hDGAT2 (HO) mice received a single subcutaneous injection of PBS (Groups 1), while HO mice in Group 2 were administered a single subcutaneous dose of ION224, a GalNAC-conjugated ASO drug (10 mg/kg). At 15 days post-dosing, liver and gonadal white adipose tissue (gWAT) were harvested to quantify human DGAT2 mRNA levels. Data were normalized to mouse GAPDH mRNA levels. Results demonstrated that ION224 significantly reduced human DGAT2 mRNA expression by 80% in the liver and approximately 50% in the gWAT compared to the PBS-treated HO group.

Abbr. HO, homozygous.